Search research articles
Contact Us
Filters
Showing results (111-120 of 209) with videos related to
Page
of 21
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
January 27, 2020
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population
Liang Zeng, Lili Xiao, Wenjuan Jiang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 1, 2020
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC
Yongchang Zhang, Liang Zeng, Chunhua Zhou, et al.
Heliyon
|
January 6, 2025
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases
Liqun Li, Zhe Huang, Yangqian Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 9, 2024
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Ying Cheng, Yun Fan, Yanqiu Zhao, et al.
Cell Reports. Medicine
|
June 30, 2026
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial
Huan Yan, Wenjuan Jiang, Yi Xiong, et al.
JCO Precision Oncology
|
March 23, 2023
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With <i>ROS1</i>-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study
Zhe Huang, Huan Yan, Liang Zeng, et al.
Recent Patents on Anti-Cancer Drug Discovery
|
July 3, 2026
A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of NHWD-870 HCl in Patients with Lymphoma and Other Advanced Solid Tumors
Mingzhu Yin, Xin Li, Zhuomiao Ye, et al.
The Lancet. Gastroenterology & Hepatology
|
October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
Rui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 3, 2020
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi, Shucai Zhang, Xingsheng Hu, et al.
Iscience
|
October 1, 2024
Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristics
Haoyue Qin, Zhe Huang, Huan Yan, et al.
Page
of 21
Search research articles
Search
Showing results (111-120 of 209) with videos related to
Sort By:
Page
of 21
Lung Cancer (Amsterdam, Netherlands)
|
January 27, 2020
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population
Liang Zeng, Lili Xiao, Wenjuan Jiang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 1, 2020
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC
Yongchang Zhang, Liang Zeng, Chunhua Zhou, et al.
Heliyon
|
January 6, 2025
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases
Liqun Li, Zhe Huang, Yangqian Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 9, 2024
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Ying Cheng, Yun Fan, Yanqiu Zhao, et al.
Cell Reports. Medicine
|
June 30, 2026
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial
Huan Yan, Wenjuan Jiang, Yi Xiong, et al.
JCO Precision Oncology
|
March 23, 2023
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With <i>ROS1</i>-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study
Zhe Huang, Huan Yan, Liang Zeng, et al.
Recent Patents on Anti-Cancer Drug Discovery
|
July 3, 2026
A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of NHWD-870 HCl in Patients with Lymphoma and Other Advanced Solid Tumors
Mingzhu Yin, Xin Li, Zhuomiao Ye, et al.
The Lancet. Gastroenterology & Hepatology
|
October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
Rui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 3, 2020
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi, Shucai Zhang, Xingsheng Hu, et al.
Iscience
|
October 1, 2024
Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristics
Haoyue Qin, Zhe Huang, Huan Yan, et al.
Page
of 21